Save information for later
Sign Up

Learn About Lennox-Gastaut Syndrome (LGS)

What is the definition of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome is a severe condition characterized by repeated seizures (epilepsy) that begin early in life. Affected individuals have multiple types of seizures, developmental delays, and particular patterns of brain activity measured by a test called an electroencephalogram (EEG). An EEG shows a slow spike-and-wave pattern during wakefulness and generalized paroxysmal fast activity during sleep.

What are the causes of Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome can have many different causes. The disorder likely has a genetic component, although the specific genetic factors are not well understood.

How prevalent is Lennox-Gastaut Syndrome (LGS)?

Lennox-Gastaut syndrome affects an estimated 1 to 2 per million people worldwide. This condition accounts for 3 to 4 percent of cases of epilepsy in children and 1 to 2 percent of cases in adults. For unknown reasons, it appears to be more common in males than in females.

Is Lennox-Gastaut Syndrome (LGS) an inherited disorder?

Most cases of Lennox-Gastaut syndrome are sporadic, which means they occur in people with no history of the disorder in their family. When Lennox-Gastaut syndrome is associated with a genetic change, the variant is usually not inherited but occurs as a random (de novo) event during the formation of reproductive cells (eggs or sperm) in an affected person's parent or during early embryonic development. However, 3 to 30 percent of people with this condition have a family history of some type of epilepsy, indicating that inherited genetic factors may play a role in some cases of Lennox-Gastaut syndrome.

Who are the top Lennox-Gastaut Syndrome (LGS) Local Doctors?
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology | General Surgery
Elite in Lennox-Gastaut Syndrome (LGS)
Neurology | General Surgery

New York University

223 E 34th St, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Orrin Devinsky is a Neurologist and a General Surgeon in New York, New York. Dr. Devinsky is rated as an Elite provider by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Seizures, Epilepsy, and Deep Brain Stimulation.

Elite in Lennox-Gastaut Syndrome (LGS)
Elite in Lennox-Gastaut Syndrome (LGS)
145 Studley Road, 
Heidelberg, VIC, AU 

John Archer practices in Heidelberg, Australia. Mr. Archer is rated as an Elite expert by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). His top areas of expertise are Lennox-Gastaut Syndrome (LGS), Epilepsy, Seizures, Absence Seizure, and Deep Brain Stimulation.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Lennox-Gastaut Syndrome (LGS)
Elite in Lennox-Gastaut Syndrome (LGS)
Paris, FR 

Rima Nabbout practices in Paris, France. Ms. Nabbout is rated as an Elite expert by MediFind in the treatment of Lennox-Gastaut Syndrome (LGS). Her top areas of expertise are Myoclonic Epilepsy, Dravet Syndrome, Epilepsy with Myoclonic-Atonic Seizures, and West Syndrome.

What are the latest Lennox-Gastaut Syndrome (LGS) Clinical Trials?
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)

Summary: This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics. The eligible participants are expected to participate in the study for a duration of 52 weeks of treatment.

Match to trials
Find the right clinical trials for you in under a minute
Get started
RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome

Summary: To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications. The intent is to determine the feasibility and the optimal design of a subsequent p...

Who are the sources who wrote this article ?

Published Date: May 03, 2023
Published By: National Institutes of Health